Post

New research · Ophthalmology
American journal of ophthalmology · 17h
Case-controlAmerican journal of ophthalmology · 2026

Assessment of Sensorimotor Complications After Plaque Brachytherapy for Patients With Uveal Melanoma.

Sara E Munkwitz, Chloe Shields, Maura Di Nicola … Michelle M Falcone
Read paper
OphthalmologyCase-control

Diplopia occurs in about 39% of patients after plaque brachytherapy for uveal melanoma.

Assessment of Sensorimotor Complications After Plaque Brachytherapy for Patients With Uveal Melanoma.

Sara E Munkwitz … Michelle M Falcone
American journal of ophthalmology · 2026
Purpose

To evaluate the incidence and characterization of diplopia and strabismus following treatment with Iodine-125 plaque brachytherapy for uveal melanoma.

Methods

With uveal melanoma treated with Iodine-125 plaque brachytherapy between May 1, 2014 and December 1, 2022.

n = 375 patients
38.9%
Results
38.9%
more than 1 in 3 patients noticed double vision after treatment
n = 375 patients
More results

A total of 375 patients (mean age 64 ± 14 years; 50.4% female) were treated with Iodine-125 plaque brachytherapy.

The incidence of sensory-deprivation related strabismus was 3.7% (14/375).

Those with worse baseline visual acuity and greater tumor distance from the optic disc had lower odds of diplopia (P = .005 and P = .026, respectively).

More results

Superior rectus muscle manipulation (P = .010), younger age (P = .045), and moderate (P = .022) or severe (P = .045) vision loss were associated with increased odds of developing strabismus.

“
Conclusion · 1 of 2

Iodine-125 plaque brachytherapy for uveal melanoma carries a moderate risk of diplopia, which typically resolves on its own. Sensory deprivation-related strabismus may also occur.

Conclusion · 2 of 2

These findings highlight that although sensorimotor complications may occur, they often resolve within 6 months postoperatively with no intervention.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
AI / Informatics
0·962 for OCT
MerMED-FM was very accurate at diagnosing diseases using eye scans
AI / Informatics
0.98
Artificial intelligence's eyelid-height measurements matched doctors' manual measurements almost perfectly
AI / Informatics
92.1%
combining eye scans and photos correctly told benign from cancerous lesions apart nearly every time
Cohort Study
28.6%
recurred locally in more than 1 in 4 patients over years of follow-up
Cohort Study
-0.395
excision group's post-op eyelid fullness score was lower - greater improvement
Cohort Study
86.7%
of infants probed after 12 months still had unresolved tear duct blockage
Observational
16%
eyelid tissue in rosacea patients showed less of this key repair-signaling protein inside cell nuclei
Cohort Study
25%
about 1 in 4 treated cases had symptoms return after improving